Panacea Biotech is up in the green today morning, with the stock price rising over 10% at Rs.127; it has come off this intra day high since then and is now at Rs.120 levels, up over 4.5%. Its 52-week high is at Rs.155.

The market is happy after it announced that it has launched a fully-liquid Tetravalent Vaccine Easyfour-TT against diphtheria, tetanus & pertussis and Haemophilus Influenza Type B.

Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO pre-qualified antigens which ensures good quality, high immurogenicity and less reactogenicity. Being fully liquid, product requires, no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.